A significant proportion of patients with Crohn disease (CD) who initially respond to infliximab therapy experience secondary loss of response with symptom flares. Treatment intensification (using increases in dose, dose frequency, or a combination of both to implement intensification) is a suggested strategy for regaining response.
A significant proportion of patients with Crohn disease (CD) who initially respond to infliximab therapy experience secondary loss of response with symptom flares. Treatment intensification (using increases in dose, dose frequency, or a combination of both to implement intensification) is a suggested strategy for regaining response. However, the development of antibodies to infliximab (ATI) negatively impacts the effectiveness of treatment intensification. Now, a new study, by Erwin Dreeson, PhD, and colleagues, published in the December 11, 2017, issue of Alimentary Pharmacology & Therapeutics, reports that therapeutic drug monitoring (TDM) of ATI concentrations can guide clinical decision-making on treatment intensification in patients with CD who have lost clinical response to infliximab.
Their retrospective cohort study was conducted in 103 Belgian patients with CD between January 2000 and October 2015. Patients who lost clinical response during infliximab maintenance therapy received an infliximab treatment intensification: 45 (44%) received a double dose; 45 (44%) underwent interval shortening, and 13 (13%) underwent combined interval shortening and dose doubling in an attempt to restore clinical response. No significant differences in baseline characteristics were found between the 3 intervention groups. Infliximab and ATI concentrations were measured via enzyme-linked immunosorbent assay (ELISA) in 2 consecutive trough samples, just before (at T0) and after (at T+1) treatment intensification.
Clinical response to infliximab treatment intensification was defined as a marked decrease in or a disappearance of symptoms (based on the physicians’ global assessment). Biological response was evaluated in the subgroup of patients with elevated C-reactive protein (CRP) before treatment intensification, and was defined as a decrease from baseline CRP of at least 50% or a normalization of CRP. Biological remission was defined as a normalization of CRP. Clinical and biological outcomes were evaluated at T+1; follow-up continued for 1 year to assess treatment discontinuation and safety issues.
The researchers report that:
The authors conclude that their data support a role for measuring ATI concentrations in the context of “reactive” TDM—that is, to regain response. However, because it is not possible to act upon the measurement at the time samples are taken, the authors suggest performing TDM in a proactive manner to preventing loss of response. “When loss of response occurs, we recommend performing dose doubling over interval shortening,” they state. In the foreseeable future, the development of point-of-care assays will allow on-site availability of the analytical result, improving flexibility of both proactive and reactive TDM. Finally, the authors say that larger cohorts must be studied to explore the cost effectiveness of TDM based on infliximab and/or ATI concentrations.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.